Emergent BioSolutions (CGT)
Baltimore, MD
Hybrid — also manufactures internal programs
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
71.0
Signal Score
○ FDA Inspections
✓ Clinical Trials (4)
✓ SEC Filings (17)
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Emergent BioSolutions (CGT)
- Signal Score
- 71.0/100 (as of 2026-09-07)
- Quality Compliance
- Assessment pending
- Headquarters
- Baltimore, MD
- Modalities
- AAV, Adenoviral
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Emergent BioSolutions (CGT)
Government contractor with viral vector capabilities.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
Operations
55.0
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Adenoviral
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Source: ClinicalTrials.gov · Retrieved Oct 07, 2026
Financial Stability
86.0
17 SEC filings with industry mentions on record
SEC Filings17 with industry mentions
Capacity
76.0
Profile-based capacity assessment
Clinical Activity 4 studies
NCT03160339
A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047
PHASE1
Terminated
NCT01979406
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of...
PHASE1
Completed
NCT00893516
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
PHASE2
Terminated
NCT00877656
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
PHASE2/PHASE3
Completed
Source: ClinicalTrials.gov · Retrieved Oct 07, 2026
Financial Intelligence
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: Anthrax - Medical Countermeasures (“MCM”) products, Naloxone Commercial products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"The Company’s solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services (“CDMO”) portfolio."
"Our solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"Commercial products, consisting of NARCAN
®
Nasal Spray and KLOXXADO
®
, Anthrax – Medical Countermeasures (“MCM”) Products, Smallpox - MCM products, and Emergent Bioservices (CDMO) (“Bioservices”)."
"Bioservices
We also compete for bioservices with several biopharmaceutical product R&D organizations, contract manufacturers of biopharmaceutical products (CDMOs), other bioservices organizations, and university research laboratories."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: Anthrax - Medical Countermeasures (“MCM”) products, Naloxone commercial products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"August 2023 Organizational Restructuring Plan
In August 2023, the Company initiated the August 2023 Plan, which was intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: Anthrax - Medical Countermeasures (“MCM”) products, Naloxone commercial products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"August 2023 Organizational Restructuring Plan
In August 2023, the Company initiated the August 2023 Plan, which was intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: Anthrax - Medical Countermeasures (“MCM”) Products, NARCAN
®
commercial product, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"August 2023 Organizational Restructuring Plan
In August 2023, the Company initiated the August 2023 Plan, which was intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth."
"Our solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"NARCAN
®
commercial product, Anthrax - Medical Countermeasures (“MCM”) Products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”
)."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services (“CDMO”) portfolio."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: NARCAN
®
commercial product, Anthrax - Medical Countermeasures (“MCM”) Products, Smallpox - MCM products and Emergent Bioservices (CDMO) (“Bioservices”)."
"Services Segment:
Bioservices - CDMO
The Company’s services revenue consists of distinct but interrelated bioservices: drug substance manufacturing; drug product manufacturing (also referred to as “fill/finish” services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: NARCAN
®
commercial product, Anthrax - Medical Countermeasures (“MCM") Products, Smallpox - MCM products and Emergent Bioservices (CDMO) ("Bioservices")."
"Services Segment:
Bioservices - CDMO
The Company’s services revenue consists of distinct but interrelated bioservices: drug substance manufacturing; drug product manufacturing (also referred to as "fill/finish" services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations."
"The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio."
"As such, the key components of the business structure include the following
four
product and service categories: NARCAN
®
commercial product, Anthrax - Medical Countermeasures (“MCM") Products, Smallpox - MCM products and Emergent Bioservices (CDMO) ("Bioservices")."
"Services Segment:
Bioservices - CDMO
The Company’s services revenue consists of distinct but interrelated bioservices: drug substance manufacturing; drug product manufacturing (also referred to as "fill/finish" services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations."
Source: SEC EDGAR · Retrieved Oct 07, 2026
Frequently Asked Questions About Emergent BioSolutions (CGT)
How many clinical programs is Emergent BioSolutions (CGT) linked to?
Emergent BioSolutions (CGT) is associated with 4 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Emergent BioSolutions (CGT)'s CDMO Signal Score?
Emergent BioSolutions (CGT) has a Signal Score of 71/100, based on quality, operations, financial stability, and capacity data.
Evaluating Emergent BioSolutions (CGT) for a manufacturing program?
Use the free AI matchmaker to compare Emergent BioSolutions (CGT) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Vigene Biosciences
Rockville, MD
Signal Score: 72.5
AAV, Lentiviral, Adenoviral
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 81.0
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
Signal Score: 79.5
Viral Vectors, AAV, Lentiviral, Adenoviral, HPAPIs, Small Molecules, Peptides, BioCatalysis, Chromatography, Cell Therapy
Exothera
Jumet, BE
Signal Score: 78.1
AAV, Adenoviral, Lentiviral
Advent Bioservices
London, United Kingdom
Signal Score: 78.1
AAV, Lentiviral, Adenoviral